Cytodyn Inc
Change company Symbol lookup
Select an option...
CYDY Cytodyn Inc
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
MMM 3M Co
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
Go

Health Care : Biotechnology |
Company profile

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Price
Delayed
$4.57
Day's Change
0.87 (23.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.73
Day's Low
3.76
Volume
(Light)

Today's volume of 5,807,639 shares is on pace to be much lighter than CYDY's 10-day average volume of 16,770,612 shares.

5,807,639

Display:

Providers:

UpdateCancel
All providers
Yesterday's News, July 13, 2020
CytoDyn's stock falls after hitting roadblock in FDA application for investigational HIV drug

Shares of CytoDyn Inc. (CYDY) fell 9.4% in trading on Monday after the company said it received a refusal to file letter from the Food and Drug Administration for its experimental HIV drug leronlimab. CytoDyn said in a news release that it is...(MarketWatch)

Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency's suggestion

Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC) for ongoing Phase 3 study (severe/critical population) is planned for...(Globe Newswire)

July 08, 2020
CytoDyn to Present at Wall Street Reporter's Livestream Event on July 9, 2020 at 1:30 pm ET / 10:30 am PT

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D...(Globe Newswire)

Important Update for CytoDyn Special Meeting of Stockholders

Change in Location of the Special Meeting to be held on July 22, 2020 Meeting Date: July 22, 2020 Meeting Time: 9:30 a.m. (Pacific Time) Meeting Access: http://www.meetingcenter.io/285700571 Due to the emerging public health impact of the...(Globe Newswire)

July 07, 2020
CytoDyn's Leronlimab Prevents Transmission of SHIV in Macaque Study

Results of preclinical study presented today in oral presentation at the 23 International AIDS Conference (AIDS 2020) CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a...(Globe Newswire)

July 06, 2020
CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn's ongoing clinical trials and FDA approval CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company")...(Globe Newswire)

July 03, 2020
CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United States

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn's ongoing clinical trials and FDA approval CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn" or the "Company")...(Globe Newswire)

CytoDyn's CEO Dr. Pourhassan to Appear on DrBeen Webcast on July 4, 2020

Dr. Pourhassan and Mobeen Syed, M.D., M.S. will discuss the Company's multi-pathway to exploring the many potential opportunities for leronlimab, including COVID-19 CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage...(Globe Newswire)

July 02, 2020
CytoDyn Releases Mechanism of Action Animation for Leronlimab in Immuno-Oncology

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the public release of the...(Globe Newswire)

July 01, 2020
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of CytoDyn Inc. ("CytoDyn" or the "Company") (OTC: CYDY) investors concerning the Company and its officers' possible...(BusinessWire)

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)

The Law Offices of Frank R. Cruz announces an investigation on behalf of CytoDyn Inc. ("CytoDyn" or the "Company") (OTC: CYDY) investors concerning the Company and its officers' possible violations of federal securities laws. (BusinessWire)

June 30, 2020
Why Biomarkers for Cancer Drug Development are Becoming Increasingly Imperative

Reports on the global market for biomarkers may vary on the dollar amount of their projections, but they all agree that there is a substantial growth in this market for years to come. One such report from Grand View Research projected that the...(PR Newswire)

June 29, 2020
CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company and the...(Globe Newswire)

June 17, 2020
"Next Super Stocks" in News: (OTC: NEXCF): Revenues Accelerating with Virtual Meetings - (OTC: CYDY): Clinical progress in COVID-19, HIV & Cancer - (OTC: KULR): Battery Tech for Electric Vehicles and Space Exploration - (OTC: IPNFF) AR Tech for "Sports 2.0" & AR-Powered Celebrity TikTok Videos

Wall Street Reporter, the trusted name in financial news since 1843, is highlighting companies which recently presented at its Next Super Stock & Investors Discovery Day livestream conference series that are making news this week. (Globe Newswire)

June 11, 2020
CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH

Preclinical results demonstrated leronlimab effectively inhibited fatty liver development CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the...(Globe Newswire)

CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication - Primary End Point Announcement Is Next

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Company has met its 75...(Globe Newswire)

June 09, 2020
Drs. Pourhassan and Kelly of CytoDyn to Hold Conference Call to Provide Updates on COVID-19 Phase 2 and 3 Trials, NASH, BLA for HIV and Manufacturing of Leronlimab in 2020-2021

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D...(Globe Newswire)

June 08, 2020
CytoDyn Receives BLA Acknowledgment Letter From the FDA

PDUFA date could be set by the FDA on July 10 CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications...(Globe Newswire)

June 01, 2020
CytoDyn to Present at Wall Street Reporter's Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D...(Globe Newswire)

CytoDyn Files Request With FDA for Priority Review of BLA for First Approval

If granted, the FDA is expected to take action on the Company's BLA within six months CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the...(Globe Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.